BioPharmaTrend
News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech

  News

Kiin Bio Raises $2.2M Pre-Seed to Build AI Platform of "Virtual Scientists" for Drug Discovery

by Roman Kasianov   •   June 6, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Biotech Ventures   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Kiin Bio, a 2024-founded startup developing an AI-native research platform for drug discovery, has raised $2.2 million in pre-seed funding led by b2venture. The company’s platform deploys “Virtual Scientists”—generative AI agents designed to plan, analyze, and orchestrate experiments across lab data, modeling tools, and analysis pipelines. Rather than replacing workflows, Kiin integrates with tools already used by R&D teams, aiming to increase output without requiring additional human hires.

#advertisement
AI in Drug Discovery Report 2025

The platform aims to target inefficiencies in pharma R&D, where siloed systems and manual processes reduce the effectiveness of AI adoption. Kiin’s approach addresses this by operating end-to-end, from hypothesis generation to experimental execution, and is structured to learn from interaction metadata (experiment plans, troubleshooting steps, and outcome histories) creating a proprietary reasoning loop that grows over time.

Kiin Bio founders: Mark Davies, Filippo Abbondanza and Bogdan Urse; Source: b2venture

Kiin licenses access on a per-agent basis, allowing smaller biotech teams to scale capacity without high upfront costs. Additional tools, models, and data can be accessed via a marketplace with transparent pricing. The system is designed to support future lab automation, positioning Kiin as a control layer for vertically integrated discovery workflows.

The founding team includes CEO Filippo Abbondanza (PhD, bioinformatics; ex-Lifebit), CDSO Mark Davies (ex-BenevolentAI), and CTO Bogdan Urse (infrastructure lead at Lifebit). Kiin is currently partnering with biotech and academic labs to refine its platform and is onboarding additional data and tooling providers to expand its ecosystem.

Topic: Biotech Ventures

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.